恩替卡韦胶囊与拉米夫定片对乙肝患者临床疗效及其安全性的分析

Analysis of Clinical Efficacy and Safety of Entecavir and Lamivudine in Patients with Hepatitis B

目的:比较恩替卡韦胶囊与拉米夫定片用于慢性乙型肝炎患者(CHB)的临床疗效和安全性。方法:选择2011年3月―2013年7月间诊治的56例CHB,将其分为A组和B组,各28例;A组患者予恩替卡韦胶囊治疗,B组患者予拉米夫定片治疗;比较两组患者治疗一年后的ALT复常率、HBe Ag阴转率、病毒抑制情况以及药物不良反应的发生率。结果:A组患者ALT复常率、HBe Ag阴转率以及药物不良反应的发生率分别为82.14%,64.29%和7.14%,其中ALT复常率和HBe Ag阴转率均显著高于B组(P<0.05);A组患者24例为完全应答,1例为部分应答,总应答率为89.29%,显著高于B组75.00%(P<0.05)。结论:恩替卡韦胶囊在CHB临床治疗中的使用可有效抑制病毒的复制,促进ALT水平的恢复,提高患者免疫能力并改善其肝功能,治疗效果与安全性均优于拉米夫定。

Objective： To compare the clinical efficacy and safety of entecavir capsule and lamivudine in patients with CHB. Methods： Fifty- six patients with hepatitis B during March 2011 and July 2013 were divided into group A and group B. Patients of group A were given entecavir capsule and patients of group B were given lamivudine treatment. Patients of two groups of ALT after inhibition rate,negative rate of HBe Ag,virus inhibition and incidence of adverse reactions after a year were compared. Results： ALT recovery rate,negative rate of HBe Ag and incidence of adverse reactions of Patients in group A were 82.14%, 64.29% and 82.14%, respectively and the ALT recovery rate and negative rate of HBe Ag were significantly higher than those of group B. Differences had statistical significance（P0.05）. A total 24 cases of Group A had complete response, 1 case for part of the response, the total response rate was 89.29%, significantly higher than that of group B 75.00%.The comparison had statistical significance（P0.05）. Conclusion： Entecavir capsule in treating chronic hepatitis B patients can effectively inhibit the viral replication, promote the recovery of the level of ALT, raise immunity and improve liver function in patients.The treatment effect is superior to lamivudine,security is higher at the same time and the clinical value is better, so it is worthy of application and promotion.